Desilets A, Blanc-Durand F, Lau S, et al. - After improved overall survival (OS) was seen with durvalumab treatment following chemoradiation (CRT) in patients with stage III non–small cell lung cancer (NSCLC) enrolled in the PACIFIC trial, researchers undertook this multicentre retrospective analysis comparing 147 patients with stage III NSCLC managed with CRT followed by durvalumab with a historical cohort of 121 patients managed with CRT alone to determine real-world factors such as optimal time to durvalumab initiation, incidence of pneumonitis, as well as response in PD-L1 subgroups. In the durvalumab group, median OS was not reached vs 26.9 months in the historical group. OS was not influenced by delay in durvalumab initiation past42 days. In durvalumab and historical groups, a similar incidence of pneumonitis was reported, though any reported pneumonitis resulted in lower 12-month OS vs those without. According to findings, favorable OS was observed in relation to PD-L1 expression ≥ 50% in patients with stage III NSCLC managed with durvalumab following CRT.